Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1982 1
1983 1
1984 1
1985 2
1986 1
1988 1
1989 2
1990 2
1991 3
1992 2
1993 4
1995 2
1996 2
1997 2
2000 1
2001 1
2005 1
2006 1
2008 1
2009 1
2010 1
2011 5
2013 3
2014 9
2015 6
2016 8
2017 5
2018 4
2019 7
2020 3
2021 8
2022 10
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

95 results
Results by year
Filters applied: . Clear all
Page 1
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Lancaster LH, et al. Among authors: albera c. Eur Respir Rev. 2017 Dec 6;26(146):170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Eur Respir Rev. 2017. PMID: 29212837 Free PMC article. Review.
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Noble PW, et al. Among authors: albera c. Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13. Lancet. 2011. PMID: 21571362 Clinical Trial.
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
Richeldi L, Fernández Pérez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G. Richeldi L, et al. Among authors: albera c. Lancet Respir Med. 2020 Jan;8(1):25-33. doi: 10.1016/S2213-2600(19)30262-0. Epub 2019 Sep 28. Lancet Respir Med. 2020. PMID: 31575509 Clinical Trial.
[Sarcoidosis].
Pescetti G, Albera C, Besso P, Cavallero M. Pescetti G, et al. Among authors: albera c. Recenti Prog Med. 1980 Mar;68(3):221-79. Recenti Prog Med. 1980. PMID: 7027376 Review. Italian. No abstract available.
Eosinophils in eosinophilic pneumonia.
Albera C, Ghio P. Albera C, et al. Eur Respir J. 1996 Dec;9(12):2437-9. doi: 10.1183/09031936.96.09122437. Eur Respir J. 1996. PMID: 8980949 Free article. No abstract available.
Assessment of Phasic Changes of Vascular Size by Automated Edge Tracking-State of the Art and Clinical Perspectives.
Mesin L, Albani S, Policastro P, Pasquero P, Porta M, Melchiorri C, Leonardi G, Albera C, Scacciatella P, Pellicori P, Stolfo D, Grillo A, Fabris B, Bini R, Giannoni A, Pepe A, Ermini L, Seddone S, Sinagra G, Antonini-Canterin F, Roatta S. Mesin L, et al. Among authors: albera c. Front Cardiovasc Med. 2022 Jan 21;8:775635. doi: 10.3389/fcvm.2021.775635. eCollection 2021. Front Cardiovasc Med. 2022. PMID: 35127855 Free PMC article. Review.
Circulating biomarkers in pulmonary arterial hypertension: update and future direction.
Pezzuto B, Badagliacca R, Poscia R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Volterrani M, Fedele F, Vizza CD. Pezzuto B, et al. Among authors: albera c. J Heart Lung Transplant. 2015 Mar;34(3):282-305. doi: 10.1016/j.healun.2014.12.005. Epub 2014 Dec 23. J Heart Lung Transplant. 2015. PMID: 25682555 Review.
95 results